Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy

被引:45
作者
Flesch, M [1 ]
Schiffer, F [1 ]
Zolk, O [1 ]
Pinto, Y [1 ]
Stasch, JP [1 ]
Knorr, A [1 ]
Ettelbruck, S [1 ]
Bohm, M [1 ]
机构
[1] BAYER AG, PHARMACOL RES INST, D-5600 WUPPERTAL, GERMANY
关键词
cardiac hypertrophy; renin-angiotensin system; diastolic dysfunction; sarcoplasmic reticulum Ca2+-ATPase; angiotensin converting enzyme inhibitors; angiotensin receptor antagonists;
D O I
10.1097/00004872-199715090-00011
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Hypertensive cardiomyopathy is a major risk factor for the development of chronic heart failure, Objective To investigate whether treatment with an angiotensin converting enzyme inhibitor (ACEI) or with an angiotensin type 1 receptor antagonist (AT(1)-RA) is sufficient to prevent the development of hypertensive cardiomyopathy and cardiac contractile dysfunction. Special emphasis was placed on the effects of both treatments on sarcoplasmic reticulum Ca2+-ATPase (SERCA 20) gene expression as a major cause of impaired diastolic cardiac relaxation. Methods and results Eight-week-old rats harboring the mouse renin 2(d) gene [TG(mREN2)27] were treated for 8 weeks with 100 mg/kg captopril (Cap) in their food and 100 mg/kg of the AT(1)-RA Bay 10-6734 (Bay) in their food. Untreated TG(mREN2)27 and Sprague-Dawley rats (SDR) were used as controls. Both treatment regimens normalized the left ventricular weight, which was increased significantly (P < 0.001) in TG(mREN2)27. Both treatments normalized the left ventricular end-systolic and end-diastolic pressures, which were significantly (P< 0.001) higher in TG(mREN2)27 than they were in SDR, and they improved the velocity of the decrease in pressure [P< 0.05, Bay and Cap versus TG(mREN2)27]. Decreased left ventricular SERCA 20 mRNA and protein levels and increased atrial natriuretic peptide messenger RNA levels were normalized by Bay and Cap treatments (P < 0.05, Bay and Cap versus TG(mREN2)27, by Northern and Western blotting). According to radioimmunoassay and an enzyme assay, respectively, Bay, but not Cap, increased plasma angiotensin I concentrations and the renin activity above normal levels (P < 0.05), whereas myocardial angiotensin II concentrations (determined by radioimmunoassay), which were significantly (P< 0.05) increased in TG(mREN2)27, were normalized equally by Bay and Cap. Conclusions In renin-induced hypertensive cardiomyopathy, left ventricular diastolic dysfunction occurs at the stage of compensated myocardial hypertrophy, The decreased left ventricular relaxation velocity might be due to reduced SERCA 20 gene expression. In this model of hypertensive cardiomyopathy, AT(1)-RA and ACEI treatments are similarly effective at reducing the arterial pressure, preventing myocardial hypertrophy and diastolic contractile dysfunction. Normalization of SERCA 2a gene expression, either by AT(1)-RA or by ACEI treatment, might contribute to the improvement in diastolic function.
引用
收藏
页码:1001 / 1009
页数:9
相关论文
共 50 条
  • [11] Impaired Ca2+ handling is an early manifestation of pressure-overload hypertrophy in rat hearts
    Chang, KC
    Schreur, JHM
    Weiner, MW
    Camacho, SA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (01): : H228 - H234
  • [12] CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
  • [13] SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION
    CHOMCZYNSKI, P
    SACCHI, N
    [J]. ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) : 156 - 159
  • [14] CROZIER J, 1995, CIRCULATION, V91, P6691
  • [15] CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85
  • [16] FUNCTION OF THE SARCOPLASMIC-RETICULUM AND EXPRESSION OF ITS CA-2+-ATPASE GENE IN PRESSURE OVERLOAD-INDUCED CARDIAC-HYPERTROPHY IN THE RAT
    DELABASTIE, D
    LEVITSKY, D
    RAPPAPORT, L
    MERCADIER, JJ
    MAROTTE, F
    WISNEWSKY, C
    BROVKOVICH, V
    SCHWARTZ, K
    LOMPRE, AM
    [J]. CIRCULATION RESEARCH, 1990, 66 (02) : 554 - 564
  • [17] COMPARISON OF THE EFFECTS OF LOSARTAN AND ENALAPRIL ON CLINICAL STATUS AND EXERCISE PERFORMANCE IN PATIENTS WITH MODERATE OR SEVERE CHRONIC HEART-FAILURE
    DICKSTEIN, K
    CHANG, P
    WILLENHEIMER, R
    HAUNSO, S
    REMES, J
    HALL, C
    KJEKSHUS, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (02) : 438 - 445
  • [18] SERUM 5-NUCLEOTIDASE
    DIXON, TF
    PURDOM, M
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1954, 7 (04) : 341 - 343
  • [19] ENALAPRIL IMPROVES SYSTEMIC AND RENAL HEMODYNAMICS AND ALLOWS REGRESSION OF LEFT-VENTRICULAR MASS IN ESSENTIAL-HYPERTENSION
    DUNN, FG
    OIGMAN, W
    VENTURA, HO
    MESSERLI, FH
    KOBRIN, I
    FROHLICH, ED
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1984, 53 (01) : 105 - 108
  • [20] GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557